This study aims to investigate the effectiveness of photobiomodulation therapy (PBMT) in the prevention and management of radiotherapy-induced vaginal toxicity (RIVT). Therefore, we hypothesize that PBMT can reduce the severity of RIVT in gynecological cancer patients, increasing the patient's QoL and sexual functioning.
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
CTCAE-score
Timeframe: Baseline
CTCAE-score
Timeframe: Two weeks post radiotherapy
CTCAE-score
Timeframe: Three months post radiotherapy
RIVT symptoms
Timeframe: Baseline
RIVT symptoms
Timeframe: Final radiotherapy session
RIVT symptoms
Timeframe: Two weeks post radiotherapy
RIVT symptoms
Timeframe: Three months post radiotherapy
RIVT symptoms
Timeframe: One year post radiotherapy